Home
Resources
Diseases
Training
SYSVAC
About
Registry
E-learning courses
News
Events
Network
Vision and Mission
Steering Committee
Map
Meetings
Join us
Home
Resources
Resources
Selected
COVID-19
Meningococcal disease
Pneumococcal disease
2023
2020
Americas
Clear all
Type of publications
NITAG documentation
(76)
Systematic reviews (SYSVAC)
(4)
Topics
Available to download in languages
Regions
Americas
(80)
Africa
(11)
Eastern Mediterranean
(3)
Europe
(38)
South-East Asia
(4)
Western Pacific
(25)
Countries
Argentina
(1)
Canada
(14)
Chile
(10)
United States of America
(53)
Diseases
COVID-19
(72)
Meningococcal disease
(3)
Pneumococcal disease
(5)
Dengue
(1)
Diphtheria
(1)
Hepatitis A
(1)
Hepatitis B
(1)
Herpes zoster
(1)
Human papillomavirus (HPV)
(5)
Influenza
(6)
Pertussis
(1)
Poliomyelitis
(1)
RSV (Respiratory syncytial virus)
(5)
Tetanus
(1)
Vaccine topics
Acceptance
(2)
Coverage
(1)
Efficacy/effectiveness
(1)
Ethical issues
(1)
Target population
Adolescents
(1)
Adults
(2)
All age groups
(2)
Children
(1)
Healthcare workers
(2)
Newborn
(2)
Older adults
(2)
Risk group
(3)
Publication date
2023
(16)
2020
(64)
2024
(3)
2022
(44)
2021
(65)
2019
(8)
2018
(9)
2017
(2)
2016
(10)
2015
(6)
2014
(8)
2013
(6)
2012
(2)
2011
(3)
2010
(5)
2009
(1)
2008
(3)
2007
(2)
2006
(3)
2005
(1)
2004
(2)
2003
(3)
2002
(2)
1997
(2)
80 results found
2023
∙
NACI
NACI Interim guidance on the use of bivalent Omicroncontaining COVID-19 vaccines for primary series
2023
∙
NACI
Guidance on an additional COVID-19 booster dose in the spring of 2023 for individuals at high risk of severe illness due to COVID-19
2023
∙
NACI
Recommendations on the use of conjugate pneumococcal vaccine – 15 valent (PNEU-C-15) and 20 valent (PNEU-C-20) in adults: Economic evidence supplementary appendix
2023
∙
NACI
Public health level recommendations on the use of pneumococcal vaccines in adults, including the use of 15-valent and 20-valent conjugate vaccines
2023
∙
NACI
Interim guidance on the use of pneumococcal 15-valent conjugate vaccine (PNEU-C-15) in pediatric populations
2023
∙
NACI
NACI guidance on COVID-19 vaccine booster doses: Initial considerations for 2023
2020
∙
Silva, S. M. Rodrigues, I. C. G. Santos, R. D. S. Ternes, Y. M. F.
The direct and indirect effects of the pneumococcal conjugated vaccine on carriage rates in children aged younger than 5 years in Latin America and the Caribbean: a systematic review
2020
∙
CAVEI
CAVEI recommendation to prioritize vaccination against SARS-COV-2 in people over 65 years in the context of limited supply of vaccines
2020
∙
Melinda Wharton, ACIP
ACIP COVID-19 Vaccine Safety Technical Sub-Group
2020
∙
Beth Bell, ACIP
ACIP COVID-19 Vaccines Work Group - overview of American vaccines in development
Home
Resources
Diseases
Training
SYSVAC
News
Events
Network
Sign in / Register